Abstract. microRNAs (miRNAs) have emerged as key regulators in many biological processes, particularly cardiac growth and development, although the specific miRNA expression profile associated with this process remains to be elucidated. This study aimed to characterize the cellular microRNA profile involved in the development of congenital heart malformation, through the investigation of single ventricle (SV) defects. Comprehensive miRNA profiling in human fetal SV cardiac tissue was performed by deep sequencing. Differential expression of 48 miRNAs was revealed by sequencing by oligonucleotide ligation and detection (SOLiD) analysis. Of these, 38 were down-regulated and 10 were up-regulated in differentiated SV cardiac tissue, compared to control cardiac tissue. This was confirmed by real-time quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) analysis. Predicted target genes of the 48 differentially expressed miRNAs were analyzed by gene ontology and categorized according to cellular process, regulation of biological process and metabolic process. Pathway-Express analysis identified the WNT and mTOR signaling pathways as the most significant processes putatively affected by the differential expression of these miRNAs. The candidate genes involved in cardiac development were identified as potential targets for these differentially expressed microRNAs and the collaborative network of microRNAs and cardiac development related-mRNAs was constructed. These data provide the basis for future investigation of the mechanism of the occurrence and development of fetal SV malformations.
Introduction
Congenital heart disease (CHD) is the most common birth defect, occurring in 4 to 8 per 1,000 live births (1) . In infants who die before term, however, there is a much higher incidence of CHD. Among these CHD lesions, single ventricle (SV) malformation, which occurs in ~1 of every 20,000 live births (2) , is a complex cardiac malformation that represents a significant therapeutic challenge. It is characterized by a single ventricle, with symptoms after birth depending on the severity and type of the defect. Symptoms include cyanosis, respiratory problems, difficulty feeding and lethargy. Without treatment patients with SV have a short life due to congestive heart failure or arrhythmias. Fifty percent of affected individuals die within 1 month of birth and 74% in the first 6 months (3).
Collective evidence indicates a role for genetic factors in the SV malformation. Three targeted single-gene disruptions in the mouse have been reported to result in SV prenatally: the Mef2c null, the dHAND/Hand2 null and the fog-2 null. All three display right ventricular hyperplasia and the fog-2 null mouse also displays a common atrioventricular orifice situated almost entirely over the future left ventricle (4) . Elucidating the genetic and molecular mechanisms underlying SV development will facilitate the development of strategies to prevent this congenital malformation. microRNAs (miRNAs) have emerged as key regulators in many biological processes, from cardiac development to disease, at almost all organismal levels through mRNA degradation or translational repression of their targets (5) . Recently, their role has been highlighted in regulating cardiac function, particularly growth and development (6) . Targeted deletion of miR-1-2 in mice resulted in 50% lethality mainly due to major ventricular wall defects (7) . The absence of miR-133a expression was associated with ectopic expression of smooth muscle genes in the heart and aberrant cardiomyocyte proliferation (8) . Disruption of miR-138 function led to ventricular expansion of gene expression normally restricted to the atrioventricular valve region and, ultimately, to disrupted ventricular cardiomyocyte morphology and cardiac function (9) . These miRNAs potentially regulate several genes encoding proteins involved in apoptosis, cell proliferation, signal transduction, transcriptional regulation and development (10) . In contrast, global changes in the expression of miRNAs during cardiac development have not been extensively investigated. This study aimed to characterize the cellular miRNAs involved in the development of congenital heart malformations, through investigation of the patterns of the SV malformation. Comprehensive miRNA profiling in human fetal cardiac tissue of SV was performed through deep sequencing. and tolerance of 3 mismatches when generating initial seeds locations; in the extension step, less than 6 mismatches were allowed in full length mapping. Acceptable sequences were compared with human miRBase database (release 14.0, http:// www.mirbase.org/) sequences (Sanger). The threshold for selection was set conservatively to include beads sampled a minimum of 10 times in any of the libraries.
Validation of differentially expressed miRNAs.
Real-time qRT-PCR was performed to confirm the differential expression of miRNAs idenitified by SOLiD sequencing. Briefly, total-RNA was isolated from fetal cardiac tissue using TRIzol (Invitrogen, Carlsbad, CA). Single-strand cDNA was synthesized as follows: the reverse transcription mixture contained 2 µl total-RNA, 1 µl hsa-miRNA reverse primer (Table I) , 1 µl ReverTra Ace, 4 µl 5X buffer, 2 µl dNTP mix (10 mM), 1 µl RNasin, 1 µl random primer and 8 µl RNase-free H 2 O (20 µl total volume). The reaction was performed at 30˚C for 10 min and 42˚C for 20 min, followed by heat inactivation at 99˚C for 5 min and a final incubation at 4˚C for 5 min. For real-time PCR, 2 µl cDNA was added to 28 µl master mix containing 0.5 µl SYBR-Green (Applied Biosystems) and 0.5 µl forward and reverse primers. cDNA was amplified over 35 cycles using the Applied Biosystems 7300 real-time PCR system. Primer sequences are shown in Table II . Data were analyzed by the iCycler™ iQ Optical System Software, Version 3.0a (Bio-Rad Laboratories). The relative level of hsa-miRNA was calculated relative to U6 RNA (internal control) using the 2 -∆∆Ct method.
Target prediction, gene ontology and Pathway-Express analysis.
A total of 48 predicted targets of miRNAs differentially expressed in SV were identified using MicroCosm (www.ebi. ac.uk/enright-srv/microcosm), TargetScan (www.targetscan. Gene name RT primer
5'-ACGAGTTTAGAGCCGGATAGCCACACAC-3' Table II . Primers for real-time RT-PCR.
Gene name Forward primer Reverse primer
org) and the microRNA.org (www.microrna.org). These were included in gene ontology (GO) analysis (http://www.babelomics.bioinfo.cipf.es/). Functional category enrichment based on the GO terms was evaluated for the targets of these differentially expressed miRNAs. Pathway-Express (http://vortex.cs.wayne. edu/) categorized the predicted targets according to KEGG pathways. A graphical representation of the network (mRNAmiRNA) of the miRNAs and their predicted targets involved in cardiac development identified by IPA analysis (http://www. ingenuity.com/) is shown in Fig. 9 .
Statistical analysis. Putative miRNA candidates were selected according to the following criteria: i) at least 10 copies by SOLiD sequencing; ii) fold-change calculated based on the normalized counts between SV cardiac tissue and control cardiac tissue, >2; iii) statistical significance of differences in expression levels between SV cardiac tissue and control cardiac tissue at P-values <0.05. Real-time qRT-PCR data are presented as the mean ± SEM.
Results
Overview of the SOLiD sequencing data. After SOLiD sequencing, raw reads were obtained from the small RNA library. Low-quality reads were removed, and the 39 adaptor sequence was trimmed. The 59 adaptor contaminants were also removed. Small RNA sequences ranging in size from 18-28 nt were retrieved from the raw data set. The size distribution of the reads is shown in Fig. 1 . The majority of the small RNAs were between 21 and 23 nt in size. Sequences of 22 nt accounted for 30.4 to 39.1% of total sequence reads in the six samples, which is the typical size range for Dicer-derived products. The 23 nt size class was also dominant.
Aberrant miRNAs in SV cardiac tissues identified by SOLiD sequencing.
A total of 48 miRNAs identified by differential expression profiling of SV and control cardiac tissue were retained for further hierarchical cluster analysis (Fig. 2) . Normalization of the raw data revealed up-regulation of 10 miRNAs and downregulation of 38 miRNAs in SV cardiac tissues compared with normal cardiac tissues (Table III) . The 48 differentially expressed miRNAs were located in the human chromosomes 14, 1 and X (19, 9 and 9%, respectively). The distribution of genomic loci in these chromosomes are shown in Fig. 3 .
Validation of differentially expressed miRNAs. SOLiD sequencing results were validated by real-time qRT-PCR expression analysis of SV and control cardiac tissues. Up-regulated miRNAs (hsa-miR-214, hsa-miR-19b and hsa-miR-126) and down-regulated miRNAs (hsa-miR-200a, hsa-miR-10a and hsa-miR-206) were selected at random for analysis. The expression data obtained by real-time qRT-PCR analysis were comparable with the microarray data (Fig. 4) . 
Target prediction, gene ontology and Pathway-Express analysis.
Predicted targets of the 48 differentially expressed miRNAs were determined using MicroCosm, TargetScan and microRNA.org. These target genes were grouped into different categories. The top 17 GO terms are shown in Fig. 5 . The majority of the targets were categorized according to cellular process, regulation of biological process, and metabolic process, thus indicating intense biological change in fetuses with SV. Pathway-Express analysis identified 22 pathways significant at the 1% level (Fig. 6) , most of which were consistent with current knowledge of cardiac development. The most significant processes putatively affected by the differential expression of miRNAs were the WNT and mTOR signaling pathways (Figs. 7 and 8, respectively) . Network of target genes involved in cardiac development and microRNAs. Ten candidate genes involved in cardiac development were identified as potential targets for microRNAs selected from the differential expression profile of SV cardiac tissues. The identification of 24 microRNAs with expression changes during cardiac development, thus contributing to the regulation of their potential targets, suggests a collaborative network of microRNAs and mRNAs involved in this process (Fig. 9 ).
Discussion
Genome-wide miRNA expression profiling was performed by deep sequencing of ventricular myocardium obtained from three spontaneously aborted fetuses with SV and three control aborted fetuses. Significant differences between miRNA expression profiles were observed between SV and control cardiac tissues. Multiple independent lines of evidence corroborate this profiling data. In this study, miRNA expression analyses by SOLiD sequencing correlated closely with real-time qRT-PCR results and were found to be in accordance with previous reports. Decreased miR-19 has been identified in the failure-prone heart (11) and down-regulation of miR-19b and miR-92a have been shown to participate in maintaining P19 cell self-renewal and inhibiting cardiac differentiation (12) . Furthermore, loss-of-function of the miR-17-92 cluster in mice resulted in smaller embryos and immediate postnatal death of all animals due to ventricular septal defects (13) . In this study, the observation that miR-19b and miR-92a were associated with the occurrence and development of fetal SV malformations is in accordance with these studies (11) (12) (13) . This study identified 48 differentially expressed miRNAs in a comparison of SV and control cardiac tissues. These included miR-133a, miR-126, miR-206 and miR-27a, which have been previously confirmed to be involved in cardiac development. The absence of miR-133a expression results in ectopic expression of smooth muscle genes in the heart and aberrant cardiomyocyte proliferation (8) . Targeted deletion of miR-126 displays defective cardiac neovascularization in mice that survive myocardial infarction (14); miR-206 is involved in apoptotic cell death in myocardial infarction by post-transcriptional repression of IGF-1 (15); and miR-27a regulation of β-MHC gene expression by targeting TRβ1 has been identified in cardiomyocytes (16) . Other differentially expressed miRNAs between SV and control cardiac tissues were not investigated and further research is required to evaluate their roles in cardiac development.
Functional roles for differentially expressed miRNAs identified in this study were categorized according to cellular process, regulation of biological process and metabolic process, thus indicating intense biological change in fetuses with SV. Pathway-Express analysis identified the WNT and mTOR signaling pathways as the most significant pathways putatively affected by the differential expression of miRNAs. Activation of WNT signaling is critical for the induction of myocardial hypertrophy and cardiomyopathy (17) . Furthermore, previous studies have shown that congenital cardiac anomalies induced by the dysfunction of myocardial cell proliferation and apoptosis are caused by dysfunction of the WNT signaling pathway (18) possibly mediated by miRNA targeting of signaling inhibitors (19) . The myocardial mTOR signaling pathway is associated with physiological and pathological hypertrophies (20) . These data provide further evidence of the mechanism of cardiac development.
Ten candidate genes (NOTCH1, WNT1, PTEN, AKT2, PDK1, TBX5, FOXP1, HAND1, GATA4 and GATA6) have been identified with an important role in cardiac development. Mice deficient in PDK1 in cardiac muscle had thinner ventricular walls, enlarged atria and right ventricles (21) and knockdown of the TBX5 gene caused cardiac failure as a result of down-regulation of cardiac myogenesis genes (22) . Furthermore, absence of HAND1 in mice results in embryonal lethality, as well as a wide spectrum of cardiac abnormalities including failed cardiac looping, defective chamber septation and impaired ventricular development (23) . The compound heterozygosity of GATA4 and GATA6 results in embryonic lethality by E13.5 accompanied by cardiovascular defects, including thin-walled myocardium, ventricular and aortopulmonary septal defects, and abnormal smooth muscle Figure 9 . Network of target genes involved in heart development and microRNAs. development (24) . These genes were identified as potential targets for miRNAs which were aberrant in SV cardiac tissues. The identification of 24 miRNAs with expression changes during development of the heart, thus contributing to the regulation of their potential targets, suggests a collaborative network of miRNAs and mRNAs involved in this process. The majority of miRNAs target more than one gene and conversely a given mRNA could be the target of several miRNAs. For example, HAND1, a basic helix-loop-helix (bHLH) transcription factor essential for mammalian heart development was identified as a potential target of five miRNAs: miR-92a, miR-let-7d, miR-let-7e, miR-266-3p and miR-335. Decreased expression of these five miRNAs leads to up-regulation of HAND1. Furthermore, miR-575 and miR-429 target genes such as GATA-4, are involved in cardiac development. It is apparent that miRNAs target genes/transcription factors that have a role in cardiac development although the collaborative network of microRNAs and mRNAs requires further investigation.
The 48 miRNAs differentially expressed in SV identified in this study provide valuable evidence for elucidation of the pathogenesis of SV. A number of these miRNAs have known cardiac development correlations, while the functions of others identified in this study remain to be investigated. Gene ontology and Pathway-Express analysis of these differentially expressed miRNAs indicated involvement in the WNT and mTOR signaling pathways. The candidate genes involved in cardiac development were identified as potential targets for these differentially expressed microRNAs and the collaborative network of microRNAs and cardiac development-related mRNAs was constructed from this information. These data provide further understanding of the mechanism underlying the occurrence and development of fetal SV malformations.
